SCHEMBL9957274

SCHEMBL9957274

[c]1cccc(-c2nc(-c3ccccc3-c3ccccc3)cc(-c3ccccc3-c3ccccc3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.39
MEN1 O00255 7/20 0.39
KMT2A Q03164 7/20 0.39
MAPT P10636 6/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
NTSR1 P30989 1/20 0.39
LMNA P02545 4/20 0.38
POLB P06746 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
MAPK10 P53779 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ADORA2A P29274 3/20 0.36
ADORA1 P30542 3/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9957555 0.86 MEN1 (0.52) MAOBMEN1KMT2AMAPTALDH1A1
SCHEMBL28644170 0.85 TSHR (0.42) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL28663752 0.80 L3MBTL1 (0.50) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL1368412 0.80 ALDH1A1 (0.41) ALDH1A1HPGDGPR55TDP1MAPK1
SCHEMBL13114113 0.80 GPR55 (0.48) MAOBMEN1KMT2AMAPTALDH1A1
SCHEMBL30733540 0.78 MEN1 (0.60) MAOBMEN1KMT2AMAPTALDH1A1
SCHEMBL2448737 0.78 ALDH1A1 (0.39) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL24604390 0.78 GPR55 (0.47) MAOBMEN1KMT2AMAPTALDH1A1
SCHEMBL17721052 0.77 MEN1 (0.53) MAOBMEN1KMT2AMAPTALDH1A1
SCHEMBL9957880 0.75 CYP1A1 (0.53) MAOBMEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MAOB 1268/4885MEN1 405/4885KMT2A 3592/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MAOB 1268/4885MEN1 405/4885KMT2A 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.